Singular Genomics Systems, Inc. Common Stock
OMIC
OMIC was delisted on the 20th of February, 2025.
69 hedge funds and large institutions have $259M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 10 reducing their positions, and 10 closing their positions.
240% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 10
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
11% more funds holding
Funds holding: 62 → 69 (+7)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
43% less capital invested
Capital invested by funds: $450M → $259M (-$191M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$34.4M |
| 2 |
BlackRock
New York
|
+$13.1M |
| 3 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$5.46M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3M |
| 5 |
PA
Perceptive Advisors
New York
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Revelation Capital Management
Sausalito,
California
|
-$23.1M |
| 2 |
DM
Deerfield Management
New York
|
-$19.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.68M |
| 4 |
JP Morgan Chase
New York
|
-$4.97M |
| 5 |
TM
Triatomic Management
Palo Alto,
California
|
-$2.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Jane Street
New York
| – | -$187K | -538 | Closed |
|
|
AGM
77
Alpine Global Management
New York
| – | -$135K | -391 | Closed |
|
|
PP
78
Paloma Partners
Greenwich,
Connecticut
| – | -$116K | -334 | Closed |
|
79
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -3 | Closed |
|
OMIC Hedge Fund Activity: Q1 2022 in Review
69 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q1 2022, worth a combined $259M — down 43% from $450M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OMIC positions and 10 closed out — a net gain of 7 holders — while 34 added to existing stakes and 10 trimmed.
The largest buyer was UBS Group, adding an estimated $34.4M. The largest seller was Revelation Capital Management, cutting an estimated $23.1M.
- 69 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q1 2022, up from 62 in Q4 2021.
- Funds reported $259M of Singular Genomics Systems, Inc. Common Stock stock for Q1 2022, down 43% quarter-over-quarter.
- 17 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of +7 holders.
- The largest Singular Genomics Systems, Inc. Common Stock buyer in Q1 2022 was UBS Group, an estimated $34.4M added.
- The largest Singular Genomics Systems, Inc. Common Stock seller in Q1 2022 was Revelation Capital Management, an estimated $23.1M sold.
Based on aggregated 13F filings for Q1 2022.